"This is a new chapter… certainly a monumental decision, a monumental day that could lead to more significant changes," former Senator Cory Gardner (R-CO), NCR Advisory Member said in an exclusive interview with Benzinga discussing the Health and Human Services (HHS) groundbreaking recommendation to the DEA about reclassifying cannabis.

The transition from cannabis being a Schedule I drug, which considers it as having no medical value and places it alongside substances like heroin, to potentially becoming a Schedule III drug is indeed noteworthy. This move would acknowledge its medical value, which has been a long-standing debate in the federal sphere.

Gardner, former Rep. Ed Perlmutter (D-CO) and senior counsel at Akin Gump Strauss, Hauer & Feld LLP, Reggie Babin will sit down together at the upcoming Benzinga Cannabis Capital Conference in Chicago. Mark your calendar for September 27 and 28.

Related Content: HHS Secretary Confirms It Is Recommending Cannabis Be Rescheduled, Per Biden's Directive

Cannabis & Politics: Is Schedule III The Future?

Speaking with Aaron Bry, content producer at Benzinga, Gardner provided an insightful perspective on the matter.

“I think in the characterizations of the steps today that I've heard, I've seen it described as monumental. I've seen it described as a very, very big event for the industry. And what it means… …

Full story available on Benzinga.com

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.